USFDA gives approval for Carboprost Tromethamine Injection

The approved product has an estimated market size of about $51.4 million for the 12 months ending March 2023, Aurobindo said citing IQVIA numbers.

104
USFDA Approval
USFDA Approval

Last Updated on October 11, 2024 by The Health Master

Aurobindo Pharma subsidiary Eugia Pharma Specialties has received the final approval from the U.S. Food and Drug Administration (USFDA) to manufacture and market Carboprost Tromethamine Injection USP 250 mcg/mL, single-dose vials.

Bioequivalent and therapeutically equivalent to Pfizer’s Hemabate Injection, 250mcg/mL, the reference listed drug, it is expected to be introduced in June.

The approved product has an estimated market size of about $51.4 million for the 12 months ending March 2023, Aurobindo said citing IQVIA numbers.

The product is indicated for aborting pregnancy between the 13th and 20th weeks of gestation and for the treatment of postpartum haemorrhage due to uterine atony.

This is the 159th approved ANDA, including eight tentative approvals received, out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products, the company said.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news